A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma

Sudeep Banerjee, David S. Wang, Hyun J. Kim, Claude B. Sirlin, Michael G. Chan, Ronald L. Korn, Aaron M. Rutman, Surachate Siripongsakun, David Lu, Galym Imanbayev, Michael D. Kuo – 30 April 2015 – Microvascular invasion (MVI) in hepatocellular carcinoma (HCC) is an independent predictor of poor outcomes subsequent to surgical resection or liver transplantation (LT); however, MVI currently cannot be adequately determined preoperatively.

Myeloid cells in hepatocellular carcinoma

Shanshan Wan, Ning Kuo, Ilona Kryczek, Weiping Zou, Theodore H. Welling – 24 April 2015 – Hepatocellular carcinoma (HCC) is highly associated with inflammation. Myeloid cells, including tumor‐associated macrophages and myeloid‐derived suppressor cells, are abundant in the HCC microenvironment and are often associated with poor prognosis. Myeloid cells in HCC play a vital role in supporting tumor initiation, progression, angiogenesis, metastasis, and therapeutic resistance.

Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based study

Lisa B. VanWagner, Jane E. Wilcox, Laura A. Colangelo, Donald M. Lloyd‐Jones, J. Jeffrey Carr, Joao A. Lima, Cora E. Lewis, Mary E. Rinella, Sanjiv J. Shah – 24 April 2015 – Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity‐related conditions with high cardiovascular mortality. Whether NAFLD is independently associated with subclinical myocardial remodeling or dysfunction among the general population is unknown.

Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation

François Faitot, Marc‐Antoine Allard, Gabriella Pittau, Oriana Ciacio, René Adam, Denis Castaing, Antonio Sa Cunha, Gilles Pelletier, Daniel Cherqui, Didier Samuel, Eric Vibert – 24 April 2015 – Liver transplantation (LT) is the best curative treatment for early hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the current shortage of organs causes prolonged waiting times and poorer intention‐to‐treat (ITT) survival (i.e., after listing) owing to tumor progression and dropout.

Subscribe to